| |JULY 20248MELODIA THERAPEUTICS & ALIVEXIS INK PACT FOR CATHEPSIN C INHIBITORBASILEA PHARMA & GLIOBLASTOMA PARTNER FOR ONCOLOGY DRUG CANDIDATEAlivexis, furthermore, Melodia Therapeutics AG, an organization set up by Forty51 Endeavors, declared that they have forayed into an exclusive license agreement for the overall development, assembling, and commercialization of Alivexis' MDI-0151, a novel Cathepsin C inhibitor with top tier potential. MDI-0151 is an imaginative clinical candidate identified in Alivexis' MOD-A discovery programme.Melodia will quickly start IND-empowering exercises for MDI-0151 to get ready for a stage 1/phase 2a study in different refractory inflammatory sicknesses brought about by unnecessary enactment of neutrophils, for example, ANCA-related Vasculitis and a few other significant illnesses with regards to neutrophils. There is a significant unmet medical need for patients with these illnesses. In order to achieve clinical Proof of Concept in these indications, Alivexis and Melodia will will leverage their respective strengths in drug discovery research and development. S. Roy Kimura,D., CEO of Alivexis, commented on the deal: "I am pleased to announce the signing of our licensing and clinical partnership with Melodia for our MOD-A Cathepsin C inhibitor programme. This event marks a significant milestone for Alivexis and serves as validation of our drug discovery R&D team and platform, our proprietary pipeline of discovery programs, and our business model involving the use of our cutting-edge platform to accelerate clinical candidate discovery for diseases with high unmet need. This is the first of many licensing and collaboration agreements that we anticipate from our maturing portfolio of IND-ready candidate molecules in our pipeline and our unique and proven discovery platform. We are confident that the Melodia team will be able to take our candidate molecule through clinical trials and ultimately help many patients in need suffering from chronic inflammatory diseases." POBasilea Pharmaceutica a commercial-stage biopharmaceutical firm with headquarters in Switzerland dedicated to treating patients with severe bacterial and fungal infections, declared that it has forayed into an asset purchase agreement with Durham-based, North Carolina, Glioblastoma Foundation Inc. for Basilea's oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma, the most common type of primary brain cancer.Dr. Marc Engelhardt, CMO of Basilea, said: "Glioblastoma is one of the most lethal types of brain cancer and available therapeutic options are very limited. Partnering lisavanbulin with the Glioblastoma Foundation is important to us, as it enables patients to continue having access to this promising anticancer drug candidate, now that Basilea has changed its strategic focus to anti-infectives."Dr. Gita Kwatra, chief executive officer of the Glioblastoma Foundation, said: "We are delighted to partner with Basilea and take over the development of lisavanbulin for glioblastoma patients. Lisavanbulin has shown excellent activity against glioblastoma in PDX preclinical models as well as efficacy in phase 1 and 2 studies. We strongly believe that lisavanbulin will be effective in a subset of glioblastoma patients and we are looking forward to initiating clinical trials of lisavanbulin in the US." POTOP STORIES
< Page 7 | Page 9 >